A non‐competitive inhibitor of PHGDH, CBR‐5884, has been identified to block the de novo synthesis of serine in melanoma and breast cancer cells, being selectively toxic for cancer cells lines with high serine biosynthesis [97]. Here, PHGDH is linked to breast carcinoma.